Spontaneous regression of a malignant tumour is a rare and incompletely understood phenomenon. It is defined as complete or partial disappearance of tumour without medical treatment, considered to be adequate for tumour disappearance.
The knowledge around this topic is mainly based upon individual case reports. Due to this event happening extremely rare (the incidence of spontaneous regression has been estimated to be not more than 1 in 60,000 - 100,000 patients)  , there are no proven data about the mechanism or inducing factors. But the fact that spontaneous regression of cancer can occur is recognized and undisputed. Several attempts of putting the reported cases of spontaneously regressing cancers have been done  -  . According to them, reasons and mechanisms of these regressions are still ambiguous and majority of case report authors cannot provide a possible cause of spontaneous regression. The factors that are supposed to be responsible for spontaneous regression include surgical interventions, immunological factors, tumour necrosis, apoptosis, epigenetic mechanisms, endocrine factors, carcinogen inactivation, psychological factors and effects of some drugs, not directly acting against cancer tissue. On cellular level the induction of spontaneous regression is completed by either cell differentiation or cell death  . In some cases tumour regression was preceded by surgical procedures  -  ; the role of infectious agents and febrile reaction  -  as well as changes in metabolic processes (especially glucose metabolism)   in the regression of cancer is also well documented.
2. Case Presentation
An elderly Caucasian woman with paranoid schizophrenia, diabetes mellitus type 2 and hypertension presented with vaginal bleeding. Her condition was continuously monitored and no other remarkable information was present in her medical history. Under general anaesthesia a gynaecological examination was performed. During examination bulky and necrotic masses, closely resembling tumour, were found in the vagina and were removed. At the same time curettage was carried out and biopsy was taken from the endometrium.
A computer tomography scan revealed: Uterine corpus size in the sagittal plane was 72 × 55 mm, slightly non-homogeneous and contained several small calcifications. At the level of the cervix a mass with enlargement of diameter up to approximately 4 cm was described (Figure 1(a)). Invasive growth from the uterus or cervix into surrounding structures was not seen. There was no free fluid present in pelvic cavity (Figure 1(b)).
Figure 1.(a) and (b) Computer tomography image of the uterine mass. The measurements are given.
Histological evaluation of all specimens, removed from cervical cavity and obtained by biopsy revealed epithelial solid fields and cribriform areas of cells with enlarged nuclei and prominent nucleoli, atypical mitoses, partly eosinophilic and mostly significantly clear cytoplasm. Clear cell component was seen in 50% - 70% of the tumour (Figure 2).
Immunohistochemical staining showed, that the tumour cells were diffusely positive for monoclonal antibodies against pancytokeratin (AE1/AE3) (Figure 5), cytokeratin 7 was positive in 5% of tumour cells (Figure 6), other markers, which showed immunoreactivity: EMA (5%), RCC-smp314 (30%), CA-125 (30%), p53 (was expressed weakly) (Figure 7), AMACR (diffuse positivity), CD10 (50%), Cyclin D1 (40% - 50%) and bcl-2. The tumour cells were negative for Vimentin (Figure 8), WT1 (Figure 9), Cytokeratin 20, ER/PR, CEA (Figure 10), TTF-1, CD57.
The final diagnosis was clear cell carcinoma of endometrium. Although relying on
Figure 2. Microscopic appearance of the endometrial tissue from curetting specimen-clear cell carcinoma, hematoxilin and eosin (H&E) staining, ×10.
Figure 3. Microscopic appearance of the endometrial tissue from curetting specimen-clear cell carcinoma, Periodic Acid- Schiff (PAS) staining, ×10.
Figure 4. Microscopic appearance of the endometrial tissue from curetting specimen-clear cell carcinoma, Periodic Acid-Schiff- diastase (PAS-D) staining, ×10.
Figure 5. Microscopic appearance of the endometrial tissue from curetting specimen-clear cell carcinoma, immunohistochemical staining with monoclonal antibodies against pancytokeratins AE1/AE3, ×10.
Figure 6. Microscopic appearance of the endometrial tissue from curetting specimen-clear cell carcinoma, immunohistochemical staining with monoclonal antibodies against cytokera- tin CK7, ×10.
Figure 7. Microscopic appearance of the endometrial tissue from curetting specimen-clear cell carcinoma, immunohistochemical staining with monoclonal antibodies against p53, ×10.
Figure 8. Microscopic appearance of the endometrial tissue from curetting specimen-clear cell carcinoma, immunohistochemical staining with monoclonal antibodies against Vimentin, ×10.
Figure 9. Microscopic appearance of the endometrial tissue from curetting specimen-clear cell carcinoma, immunohistochemical staining with monoclonal antibodies against WT1, ×10.
Figure 10. Microscopic appearance of the endometrial tissue from curetting specimen-clear cell carcinoma, immunohistochemical staining with monoclonal antibodies against CEA, ×10.
immunohistochemical pattern a definite differentiation between clear cell carcinoma of endometrium and endocervix was not possible. But endocervical cancer would be expected to be CEA positive. Primary ovarian carcinoma was less probable because of WT1 negativity.
Taking into consideration the general condition of the patient, neither surgical, nor chemo-radiotherapy was considered possible.
After the gynaecologic examination with removal of the bulky masses the general condition of the patient improved. No episodes of vaginal bleeding were reported. The patient continued treatment with psychotropic drug (Risperdal 2 mg) and continuously received Metformin.
No further follow-ups were possible due to the psychiatric condition of the patient.
13 months later the patient died. The pathologist performed an autopsy in attendance of the treating psychiatrist. At autopsy extensive areas of necrotizing inflammation and abscess were found in liver (Figure 11). Sepsis and bacteraemia were confirmed. In addition there were multiple inflammatory areas around the pancreas. A focus of myocardial infarction (weeks or months old) was detected with extensive athero- sclerosis of coronary arteries. No carcinoma could be found in uterine corpus or cervix (Figures 12-14). Only presence of adenomyosis and leiomyoma was described in uterine corpus. Myocardial infarction, aggravated by poor functional status of organism due to sepsis, was concluded to be a cause of death.
Although the precise mechanism of tumour regression is unknown, our case demonstrates that clear cell carcinoma of the endometrium may spontaneously regress.
The possibility that the tumour was completely removed by combination of manual removal, curettage and biopsy is unlikely because in the histological specimens only tumour was seen without any fragment of normal endometrial tissue. Several mechanisms of tumour regression can be discussed to explain this case.
Figure 11. Microscopic appearance of the liver tissue from post- mortem examination, H&E staining, ×2.5.
Figure 12. Macroscopic appearance of uterine cervix and corpus from gross examination of post-mortem specimen.
Figure 13. Microscopic appearance of the cervical tissue from post-mortem examination-no pathological changes, H&E staining, ×1.25.
Figure 14. Microscopic appearance of the endometrial and myometrial tissue from post-mortem examination-uterine leiomyoma is seen, H&E staining, ×1.25.
Described cases of tumour regression explained with usage of similar psychotropic drug, to that used in treatment of this particular patient couldn’t be found in the literature. Investigations around the possible mechanism for Risperdal to induce cancer regression were also not successful.
There is convincing evidence of glucose metabolism and factors affecting it being important for tumour cell survival, progression and regression of tumours  -  . One recent study has suggested using ketogenic diet in combination with metformin as a potential treatment for cancer diseases  . Some studies suggest that metformin may also target the inflammatory component present in the microenvironment of most neoplastic tissues, leading to tumour reduction. In addition, inhibition of neoplastic angiogenesis by metformin might also participate in the reduction of tumour growth   . Another study on breast cancer states that metformin has an ability to selectively kill cancer stem cells and to function synergistically with chemotherapeutic agents to block both cancer stem cells and non-stem transformed cells  . Other researchers have also come to similar conclusions   .
It may be possible that the tumour regressed as a reaction of the body to dissemination of tumour cells via the blood and lymphatic vessels. Such dissemination may produce a sudden tumour-antigen load of sufficient magnitude to stimulate a substantial anti-tumour immune response. There have been several reports of such effect, for example, post-fine needle aspiration biopsy necrosis of thyroid tumours   .
The role of infectious agents in the regression of cancer may also be a possibility. Bacteraemia, necrotizing inflammation and abscesses may have been a reason of tumour regression by activating whole cascade of potential anti-tumoral processes  . In addition bacterial endotoxins increase lymphocyte activity, stimulate the secretion of tumour necrosis factor and suppress the formation of new blood vessels, which are vital for the growth of tumour   . There are reports about remission in leukemia, associated with pyogenic infections  . In a syngeneic mouse model pancreatic cancer has been found to regress in response to intratumoural injections of living Streptococcus pyogenes  .
Other popular hypotheses to explain tumour regression include changes in diet, intake of nutritional supplements, herbal medications, hormones and steroids. In our case the role of these factors is extremely unlikely.
There are a small number of cases of spontaneously regressing gynaecological malignancies reported   . Although Everson reported two cases of endometrial carcinoma with spontaneous regression, none of them demonstrated long-term survival  . One more case was documented by Beller et al.  . A 56-year-old woman was alive without recurrent disease 18 years from primary diagnosis. Another case was described by Parker et al.  . A 73-year-old woman with essential thrombocytosis and metastasized clear cell endometrial carcinoma received no therapy and remained disease-free 6 years later.
 Abdelrazeq, A.S. (2007) Spontaneous Regression of Colorectal Cancer: A Review of Cases from 1900 to 2005. International Journal of Colorectal Disease, 22, 727-736.
 Thotathil, Z. and Jameson, M.B. (2007) Early Experience with Novel Immunomodulators for Cancer Treatment. Expert Opinion on Investigational Drugs, 16, 1391-1403.
 Malezki, C., Linnebacher, M., Reikemeyer, B. and Emmrich, J. (2008) Pancreatic Cancer Regression by Intratumoural Injection of Live Streptococcus pyogenes in a Syngeneic Mouse Model. Gut, 57, 483-491.
 Bowker, S.L., Yasui, Y., Veugelers, P. and Johnson, J.A. (2010) Glucose-Lowering Agents and Cancer Mortality Rates in Type 2 Diabetes: Assessing Effects of Time-Varying Exposure. Diabetologia, 53, 1631-1637.
 Oleksyszyn, J., Wietrzyk, J. and Psurski, M. (2014) Cancer: Could It Be Cured? A Spontaneous Regression of Cancer, Cancer Energy Metabolism, Hyperglycemia-Hypoglycemia, Metformin, Warburg and Crabtree Effects and a New Perspective in Cancer Treatment. Journal of Cancer Science & Therapy, 6, 56-61.
 Niakan, B. (2010) Spontaneous Remission of Cancer: Steady and Aggressive Malignant Growth Faced with Hypoxia or Hypoglycemia. Medical Hypotheses, 75, 505-506.
 Oleksyszyn, J. (2011) The Complete Control of Glucose Level Utilizing the Composition of Ketogenic Diet with the Gluconeogenesis Inhibitor, the Anti-Diabetic Drug Metformin, as a Potential Anti-Cancer Therapy. Medical Hypotheses, 77, 171-173.
 Violle, B., Bruno Guigas, B., Sanz Garcia, N., Leclerc, J., Foretz, M. and Andreelli, F. (2012) Cellular and Molecular Mechanisms of Metformin: An Overview. Clinical Science, 122, 253-270.
 Xavier, D.O., Amaral, L.S., Gomes, M.A., Rocha, M.A., Campos, P.R., Cota, B.D., et al. (2010) Metformin Inhibits Inflammatory Angiogenesis in a Murine Sponge Model. Biomedicine & Pharmacotherapy, 64, 220-225.
 Hirsch, H.A., Iliopoulos, D., Tsichlis, P.N. and Struhl, K. (2009) Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission. Cancer Research, 69, 7507-7511.
 Janzera, A., German, N.J., Gonzalez-Herrera, K.N., Asarac, J.M., Haigis, M.C. and Struhl, K. (2014) Metformin and Phenformin Deplete Tricarboxylic Acid Cycle and Glycolytic Intermediates during Cell Transformation and NTPs in Cancer Stem Cells. Proceedings of the National Academy of Sciences of the United States of America, 111, 10574-10579.
 Lonardo, E., Cioffi, M., Sancho, P., Sanchez-Ripoll, Y., Trabulo, S.M., Dorado, J., et al. (2013) Metformin Targets the Metabolic Achilles Heel of Human Pancreatic Cancer Stem Cells. PLoS ONE, 8, e76518.
 Fujimoto, N., Nakanishi, G., Kabuto, M., Nakano, T., Eto, H., Nakajima, H., Sano, S. and Tanaka, T. (2015) Merkel Cell Carcinoma Showing Regression after Biopsy: Evaluation of Programmed Cell Death 1-Positive Cells. Journal of Dermatology, 42, 496-499.
 Herreros-Villanueva, M., Hijona, E., Cosme, A. and Bujanda, L. (2012) Spontaneous Regression of Pancreatic Cancer: Real or a Misdiagnosis? World Journal of Gastroenterology, 18, 2902-2908.
 Parker, R., Lanvin, D., Gilks, B. and Miller, D. (2001) Spontaneous Regression of Stage IV Clear Cell Carcinoma of the Endometrium in a Patient with Essential Thrombocytosis. Gynecologic Oncology, 82, 395-399.